

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 199669427 B2
(10) Patent No. 728524

(54) Title
Stable compositions containing N-propargyl-1-aminoindan

(51)⁷ International Patent Classification(s)
A61K 031/00

(21) Application No: **199669427**

(22) Application Date: **1996.09.18**

(87) WIPO No: **WO97/12583**

(30) Priority Data

(31) Number	(32) Date	(33) Country
115357	1995.09.20	IL

(43) Publication Date : **1997.04.28**

(43) Publication Journal Date : **1997.06.19**

(44) Accepted Journal Date : **2001.01.11**

(71) Applicant(s)
Teva Pharmaceutical Industries Ltd.

(72) Inventor(s)
Tirtsah Berger Peskin; Fanny Caciularu

(74) Agent/Attorney
PIZZEYS,GPO Box 1374,BRISBANE QLD 4001

OPI DATE 28/04/97 APPLN. ID 69427/96
AOJP DATE 19/06/97 PCT NUMBER PCT/IL96/00115



AU9669427

D)

(51) International Patent Classification :

A61K 31/00

SEARCH QUALITY ASSURANCE

A2

(11) International Publication Number:

WO 97/12583

(43) International Publication Date:

10 April 1997 (10.04.97)

(21) International Application Number: PCT/IL96/00115

(22) International Filing Date: 18 September 1996 (18.09.96)

(30) Priority Data:

115357

20 September 1995 (20.09.95) IL

(71) Applicant (for all designated States except US): TEVA PHARMACEUTICAL INDUSTRIES LTD. [IL/IL]; Science Based Industries Campus, Har Hotzvim, P.O. Box 1142, 91010 Jerusalem (IL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BERGER PESKIN, Tirtzah [IL/IL]; 43 Kazan Street, 43611 Raanana (IL). CACI-ULARU, Fanny [IL/IL]; 17 Shapira Street, 49491 Petach Tikva (IL).

(74) Agent: INGEL, Gil; Reinhold Cohn and Partners, P.O. Box 4060, 61040 Tel Aviv (IL).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: STABLE COMPOSITIONS CONTAINING N-PROPARGYL-1-AMINOINDAN

(57) Abstract

A pharmaceutical composition comprising as active ingredient a racemic, S(-), and R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof, and at least 60 % by weight of at least one pentahydric or hexahydric alcohol. Optionally the composition may contain citric acid and magnesium stearate.

- 1 -

STABLE COMPOSITIONS CONTAINING N-PROPARGYL-1-AMINOINDAN

FIELD OF THE INVENTION

The present invention concerns formulations of racemic, S(-) or R(+) enantiomers of N-propargyl-1-aminoindan, and especially formulations of the enantiomer R(+) of N-propargyl-1-aminoindan (referred to hereinafter as R(+) PAI) which is a selective irreversible inhibitor of the B-
5 form of the enzyme monoamine oxidase used, for example, for the treatment of Parkinson's disease. In the following the enzyme monoamine oxidase will be referred to as MAO and the B-form thereof as MAO-B.

10 BACKGROUND OF THE INVENTION

GB 1 003 686 discloses a group of benzocycloalkane compounds in which the cycloalkane has from five to seven ring members and is substituted by an N-(alkynylalkyl)amino group, and their use as MAO inhibitors. The patent further discloses the use of the subject compounds in
15 admixture with a variety of substances including various alcohols such as a benzyl alcohol, stearyl alcohol, and methanol. The patent, however, does not teach how and by what criteria any of the many possible carriers and other ingredients are selected so as to overcome the stability problem of the product.

- 2 -

The object of the present invention is to provide stable formulations comprising an effective amount of racemic, S(-) or R(+)-N-propargyl-1-aminoindan. For the sake of simplicity, the abbreviation PAI, unless specified otherwise, will be used to denote the enantiomers of N-propargyl-1-aminoindan, as well as their racemic mixtures.

SUMMARY OF THE INVENTION

In accordance with the invention it was surprisingly found that the stability of formulations comprising PAI can be significantly improved by the incorporation of relatively large amounts of certain alcohols.

In accordance with the present invention there is provided a pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of a compound being a member selected from the group of racemic, S(-), and R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof, and at least 60% by weight of at least one alcohol being a member selected from the group of pentahydric and hexahydric alcohols.

In a preferred embodiment of the present invention the active ingredient is R(+)-N-propargyl-1-aminoindan.

Preferably the composition comprises at least 70% of said at least one alcohol.

Typically the alcohol used in accordance with of the invention, is a member selected from the group of mannitol, xylitol and sorbitol.

In accordance with the invention the PAI-comprising composition may further include citric acid, preferably in an amount of 0.5 to 2% by weight.

If desired, compositions according to the invention may further comprise magnesium stearate, preferably in an amount of 0.1 to 0.5% by weight. According to this embodiment, where the amount of said at least one alcohol is less than 70% by weight, the composition further comprises citric acid in an amount specified above. Where the amount of said at least one alcohol is at least 70% by weight, the inclusion of citric acid is optional.

- 3 -

The composition of the present invention may optionally also include conventional additives such as fillers, lubricants, disintegrants, glidants, flavoring agents, sweeteners, coloring agents, and the like, all as known *per se*. Examples of fillers which may be used in accordance with the present invention are lactose, starch, microcrystalline cellulose, maltrin and the like.

The compositions of the present invention may be prepared by methods known *per se*, familiar to those skilled in the art. For example, PAI and all other ingredients (with the exception of the lubricant, when used) may be screened and mixed thoroughly in a suitable granulating machine. The granulation may occur in the presence of purified water, following which the composition is dried. The dry granulate may then be milled, lubricated and compressed into tablets. R(+) PAI itself may be prepared, for example, according to the process described in Example 6B of WO95/11016.

The following non-limiting examples are given by way of illustration.

EXAMPLES

EXAMPLE 1

	mg/tablet
R(+)-N-propargyl-1-aminoindan mesylate	3.12
Mannitol	62.5
Maltodextrin (Maltrin 150)	36.0
Croscarmellose sodium (Ac-Di-Sol)	2.1
Talc	1.5

- 4 -

EXAMPLE 2

	mg/tablet
R(+)-N-propargyl-1-aminoindan mesylate	1.56
5 Mannitol	79.14
Starch	10.0
Pregelatinized starch	10.0
Colloidal silicon dioxide	0.6
Talc	2.0
10 Stearic acid	2.0

EXAMPLE 3

	mg/tablet
15 R(+)-N-propargyl-1-aminoindan mesylate	3.12
Mannitol	76.58
Starch	10.0
Pregelatinized starch	10.0
20 Colloidal silicon dioxide	0.6
Citric acid	1.0
Talc	2.0

25

EXAMPLE 4

	mg/tablet
R(+)-N-propargyl-1-aminoindan mesylate	3.12
Mannitol	69.88
30 Lactose (hydrous)	14.0
Starch	14.0
Glyceryl Behenate (Compitrol 888 ATO)	2.0

- 5 -

EXAMPLE 5

	mg/tablet
5 R(+)-N-propargyl-1-aminoindan mesylate	3.12
Mannitol	77.28
Starch	10.0
Starch STA-RX 1500	10.0
Colloidal silicon dioxide, Aerosil	0.6
10 Hydrogenated vegetable type I (Sterotex Dritex)	2.0

EXAMPLE 6

15 In order to compare the compositions of the present invention with those known in the prior art, two of the above formulations were compared with a formulation described in WO95/11016.

Formulation of WO95/11016 (Example 20)

	mg/tablet
20 R(+)-N-propargyl-1-aminoindan HCl	1.56
Lactose (hydrous)	50.0
Pregelatinized starch	36.0
Microcrystalline cellulose	14.0
25 Sodium starch glycolate	2.14
Talc	1.0
Magnesium stearate	0.5

30 This formulation, as well as those described under Examples 2 and 3 of the present application were subjected to 6 months at 40°C and 75% humidity. The percentage of degradants of the active material was assayed at the end of the six month period.

- 6 -

The following procedure was adopted to determine the degradation of the formulations prepared. The tablets were finely powdered and extracted with a diluent such as a mixture of water, acetonitrile and perchloric acid. An aliquot of the extraction product was injected into an HPLC and eluted using the same mixture as said diluent mixture. The area corresponding to the PAI compound was determined as was that of any other major peak. The calculations of degradation percent was made by comparing the areas of the measured peaks with those obtained from the standard preparation.

It was found that the formulation prepared according to the disclosure of Example 20 of WO95/11016 contained after storage 3.08% degradants whereas the formulations of Examples 2 and 3 contained 0.51% and less than 0.1% degradants, respectively.

EXAMPLE 7

Formulations according to the present invention and others according to the description given in Example 20 of WO95/11016 were prepared containing the ingredients shown in Table 1. The formulations described in this Table are designated "PCT" when prepared in accordance with the disclosure in WO95/11016, or by a number which corresponds to the number of the Example in the present application, in which they are described. The qualifying symbols of A, B, C or D appearing next to some of these designations denote certain variations in said formulations. The percentage of degradation, presented in Table 2, was calculated for all the formulations of Table 1, after storing them for 1 month at 55°C or for 6 months at 40°C and 75% humidity. Those formulations stored according to the latter storing conditions are marked in the Table with an astrix (*). As can be seen from Table 2, the stabilities of all the compositions of the present invention was superior to those of the prior art.

TABLE I

Example No.	PCT	PCT-A	PCT-B	PCT-C	1	1A	1B	1C	1D	2	2A	3	3A	4	5	5A	5B	5C	8	9
	mg	mg	mg	mg	mg	mg	mg	mg	mg	mg	mg	mg	mg	mg	mg	mg	mg	mg	mg	mg
N-Propargyl-1(R)-Amidin Mesylate	1.56	5.0	1.0	7.81	3.12	3.12	1.56	3.12	1.56	1.56	1.56	3.12	1.56	3.12	3.12	1.56	1.56	1.56	1.56	1.56
Mannitol USP					62.5	62.5				79.14	78.44	76.58	77.44	69.88	77.28	78.87	78.87	78.87		
Starch ST-A-1X 1500	36.0	47.0	36.0	47.0			36.0	36.0	36.0	10.0	10.0	10.0	10.0		10.0	10.0	10.0	10.0	10.0	10.0
Starch NF (in paste)										5.6	10.0	5.6	10.0	14.0	10.0	10.0	10.0	10.0	10.0	10.0
Colloidal Silicon Dioxide (Aerosil 200)										0.6	0.6	0.6	0.6		0.6	0.6	0.6	0.6	0.6	0.6
Citric acid								1.0	2.0			1.0	1.0							
Talc USP	1.0	1.5	1.0	1.5	1.5	1.5	1.0	1.0	1.0	2.0	2.0	2.0	2.0			2.0	2.0	2.0	2.0	2.0
Microcrystalline Cellulose (Avicel 102)	14.0	20.0	14.0	20.0			14.0	14.0	14.0											
Stearic acid NF							2.0			2.0	2.0	2.0	2.0			2.0		2.0	2.0	2.0
Lactose NF Hydrated	50.0	66.0	50.0	66.0			50.0	47.44	46.44					14.0						
Sodium Starch Glycolate	2.14	3.0	2.2	2.99			2.14	2.14	2.14											
Magnesium Stearate	0.5	0.7	0.5	0.7		0.52	0.1	0.5	0.5							0.1	0.5	0.5		
AC-DI-SOL					2.1	2.1														
Lactose spray dried																				
Combitol 880 ATO																				
Maltin					36.0	36.0								2.0						
Sorbitol																			78.84	
Xilitol 300																				78.84
Sterolex - Durex															2.0					
Total Weight (mg)	105.2	143.2	104.7	146.0	105.22	105.74	106.8	105.2	105.2	105.3	104.6	105.3	104.6	103.0	103.0	105.13	103.53	105.53	105.0	105.0

Table 2

Example No:	% Degradants	Manitol (%)	Sorbitol (%)	Xylitol (%)	Magnesium stearate (%)	Citric acid (%)
PCT(*)	2.26	-	-	-	0.5	-
PCT-A	2.76	-	-	-	0.49	-
PCT-B	1.46	-	-	-	0.49	-
PCT-C(*)	2.59	-	-	-	0.5	-
1	1.22	59.4	-	-	-	-
1A	3.97	59.1	-	-	0.49	-
1B	2.04	-	-	-	0.1	-
1C	1.04	-	-	-	0.47	0.95
1D	0.40	-	-	-	0.47	1.9
2	0.29	75.1	-	-	-	-
2A	0.27	75	-	-	-	-
3	0.02	72.7	-	-	-	0.95
3A	0.02	74	-	-	-	0.95
4	0.02	67.8	-	-	-	-
5	0.21	75	-	-	-	-
5A	0.32	75	-	-	0.1	-
5B	0.65	76.2	-	-	0.47	-
5C	0.52	74.7	-	-	0.47	-
6	0.74	-	75.1	-	-	-
7	1.01	-	-	75.1	-	-

Claims:

1. A pharmaceutical composition in tablet form comprising as an active ingredient a therapeutically effective amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof, and at least one alcohol selected from the group consisting of pentahydric and hexahydric alcohols, wherein said at least one alcohol comprises at least 60% by weight of the total composition.
2. The pharmaceutical composition of claim 1, wherein the amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof is in the range of 3% or less by weight of the composition.
3. The pharmaceutical composition according to claims 1 or 2, wherein the alcohol is selected from the group consisting of mannitol, xylitol and sorbitol.
4. The pharmaceutical composition according to any one of claims 1 to 3, further comprising citric acid.
5. The pharmaceutical composition of claim 4, wherein the amount of citric acid is 0.5 to 2% by weight of the total composition.
6. The pharmaceutical composition according to any one of claims 1 to 5, further comprising magnesium stearate.
7. The pharmaceutical composition of claim 6, wherein the amount of magnesium stearate is 0.1 to 0.5% by weight of the total composition.
8. The pharmaceutical composition according to any one of claims 1 to 7, in which the amount of said at least one alcohol is between 60% and 70% of the total composition, and further comprising citric acid.
9. The pharmaceutical composition according to any one of the preceding claims, wherein said active ingredient is R(+)-N-propargyl-1-aminoindan.



10. A pharmaceutical composition in tablet form comprising as an active ingredient a therapeutically effective amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof, and at least 75% by weight of at least one alcohol selected from the group consisting of mannitol, xylitol and sorbitol.
11. The pharmaceutical composition of claim 10, wherein the amount of R(+) -N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof is in the range of 3.0% or less by weight of the composition, and wherein the alcohol at least 75% by weight of the composition.
12. The pharmaceutical composition of claim 11, wherein the alcohol is mannitol.
13. The pharmaceutical composition of claim 2, wherein the amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof is 1.5% of the total composition.
14. The pharmaceutical composition of claim 2, wherein the amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof is 0.96% of the total composition.
15. The pharmaceutical composition of claim 10, wherein the amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof is 1.5% of the total composition.
16. The pharmaceutical composition of claim 10, wherein the amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof is 0.96% of the total composition.

DATED THIS TWENTY-SIXTH DAY OF OCTOBER 2000.

TEVA PHARMACEUTICAL INDUSTRIES LTD

By
PIZZEYS PATENT AND TRADE MARK ATTORNEYS

